Alpha-synuclein overexpressing neurons are disease model neurons that overexpress the SNCA gene encoding the alpha-synuclein protein. These models replicate the proteinaceous inclusions known as Lewy bodies and Lewy neurites, which are pathological hallmarks of Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). These neurons are typically generated through viral vector-mediated gene delivery or derived from iPSCs carrying SNCA duplication/triplication mutations.
| Property |
Value |
| Category |
Disease Model Neurons |
| Location |
Substantia nigra, cortex, other brain regions (model) |
| Cell Types |
AAV-Syn overexpression, iPSC-derived SNCA triplication neurons |
| Primary Neurotransmitter |
Dopamine (nigral), Glutamate (cortical) |
| Key Markers |
Alpha-synuclein, Phospho-Ser129, TH, NeuN |
Alpha-synuclein is a 140-amino acid protein predominantly expressed in presynaptic terminals. Its normal functions include:
- Synaptic vesicle regulation: Modulates synaptic vesicle pools and release
- Dopamine synthesis: Influences tyrosine hydroxylase activity
- Chaperone activity: Involved in protein folding homeostasis
- Membrane binding: Associates with synaptic vesicles
In disease states, alpha-synuclein undergoes:
- Misfolding: Conformational change from alpha-helix to beta-sheet
- Oligomerization: Formation of toxic soluble oligomers
- Fibrillization: Aggregation into insoluble fibrils
- Inclusion formation: Lewy body and Lewy neurite development
¶ SNCA Mutations and Copy Number Variants
- A53T (SNCA^A53T): Early-onset familial PD
- A30P (SNCA^A30P): Reduced membrane binding
- E46K (SNCA^E46K): Increased aggregation
- SNCA duplication: Sporadic PD risk factor
- SNCA triplication: Parkinsoid syndrome (Dementia-Parkinsonism)
- Lewy body-like inclusions: Cytoplasmic aggregates
- Lewy neurites: Axonal and dendritic inclusions
- Phospho-Ser129 alpha-synuclein: Pathological phosphorylation
- Ubiquitin-positive aggregates: Proteostasis impairment
- Reduced synaptic vesicle number: Depleted vesicle pools
- Impaired dopamine release: Synaptic transmission deficits
- Synaptic protein loss: Synaptophysin reduction
- Neuronal connectivity deficits: Reduced dendritic branching
- Complex I impairment: Electron transport chain defects
- Mitochondrial fragmentation: Altered dynamics
- Reduced ATP production: Bioenergetic failure
- Increased mitochondrial ROS: Oxidative stress
- Lysosomal dysfunction: Reduced autophagic clearance
- ER stress: Unfolded protein response activation
- Proteasomal inhibition: Impaired protein degradation
- Aggregate seeding: Spreading pathology
Soluble oligomeric forms of alpha-synuclein are considered the most toxic species:
- Membrane pore formation: Causing ion dysregulation
- Mitochondrial damage: Direct interaction with mitochondria
- Synaptic dysfunction: Presynaptic terminal impairment
- Spread prion-like behavior: Intercellular propagation
Alpha-synuclein pathology can spread via:
- Release: Secretion from affected neurons
- Uptake: Internalization by neighboring cells
- Template-directed misfolding: Inducing endogenous protein aggregation
- Network spread: Connectome-dependent propagation
- Microglial activation: Enhanced by extracellular alpha-synuclein
- Cytokine release: IL-1β, TNF-α, IL-6 elevation
- Oxidative stress: NADPH oxidase activation
- Neuronal damage amplification: Inflammatory cascade
- Protein aggregation modeling: Lewy body formation
- Synaptic dysfunction studies: Dopamine release impairment
- Prion-like spreading: Pathology propagation mechanisms
- Therapeutic target validation: Oligomer and aggregation inhibitors
Alpha-synuclein overexpressing neurons enable study of:
- Sporadic and familial PD mechanisms
- Lewy body dementia pathology
- Multiple system atrophy progression
- Therapeutic intervention effects
- Small molecule inhibitors: E.g., Anle138b, CLR01
- Antibody therapies: Anti-alpha-synuclein antibodies
- Molecular tweezers: CLR01 (molecular disruptor)
- Autophagy enhancers: Rapamycin, Trehalose
- Lysosomal activators: GBA gene therapy
- Immunotherapies: Active and passive vaccination
- Antioxidants: MitoQ, N-acetylcysteine
- Glutamate antagonists: NMDA receptor modulators
- Growth factors: GDNF, BDNF
These models enable:
- High-throughput screening for aggregation inhibitors
- Target engagement studies
- Mechanism of action determination
- Biomarker development
- Phospho-Ser129: Pathological alpha-synuclein marker
- Total alpha-synuclein: CSF and blood biomarker
- Oligomeric alpha-synuclein: Toxic species detection
- Neurofilament light chain: Neurodegeneration marker
The study of Alpha Synuclein Overexpressing Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Spillantini MG, et al. Alpha-synuclein in Lewy bodies. Nature. 1997
- Lashuel HA, et al. The many faces of alpha-synuclein: from structure to neurotoxicity. J Mol Biol. 2002
- Kalia LV, et al. Parkinson's disease. Lancet. 2015
- Prusiner SB, et al. Evidence for alpha-synuclein prions causing multiple system atrophy in humans. Proc Natl Acad Sci. 2018
- Venda LL, et al. Alpha-synuclein and dopamine at the crossroads of Parkinson's disease. Trends Neurosci. 2010